Monopar Therapeutics Inc. cash flow to debt ratio of -7.88K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Monopar Therapeutics Inc.'s free cash flow has decreased 90.52% from $-6.40M last year to $-12.20M, signaling decreasing performance

Monopar Therapeutics Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Monopar Therapeutics Inc. has insufficient data to evaluate this check.

Monopar Therapeutics Inc. has a net cash position, so leverage is healthy.

Monopar Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Monopar Therapeutics Inc. has insufficient data to evaluate this check.

Monopar Therapeutics Inc.'s short-term assets of $140.46M exceed its short-term liabilities of $2.74M

Monopar Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Monopar Therapeutics Inc.'s return on equity of -12.84%, is lower than 15.00%, indicating bad performance

Monopar Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Monopar Therapeutics Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Monopar Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Monopar Therapeutics Inc. has negative free cash flow, indicating cash burn

Monopar Therapeutics Inc.'s yearly earnings has increased -11.99% since last year from $-15.59M to $-13.72M, signaling increasing performance

Monopar Therapeutics Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -13.80% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Monopar Therapeutics Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Monopar Therapeutics Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Monopar Therapeutics Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Monopar Therapeutics Inc. is undervalued relative to its fair value price of 8.79K based on Discounted Cash Flow model

Monopar Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Monopar Therapeutics Inc. is undervalued relative to its fair value price of 9.20K based on EBITDA multiple model

Monopar Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Monopar Therapeutics Inc. has insufficient data to evaluate this check.

Monopar Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Monopar Therapeutics Inc. has a price-to-book ratio of 7.33x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Monopar Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue